ClinicaliQ Trial Snapshot
- A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures — Recruiting • Phase III • Neurology • NCT05077904.
- This trial tests whether inhaled alprazolam stops prolonged seizures faster than placebo in people aged 12+.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration. Conditions: Stereotypical Prolonged Seizures Interventions: Staccato alprazolam, Placebo Lead Sponsor: UCB Biopharma SRL Planned Enrollment: 350 participants